In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cardinal.com: The New Old Thing

Executive Summary

Often overlooked in the debate over who's going to win the Internet wars, Cardinal makes its case for a distributor-driven model. A single place to purchase drugs and med/surg supplies, do remote order entry, and more efficiently process information, Cardinal.com builds off of traditional EDI programs. Like many e-commerce plays, Cardinal.com recognizes the value of an open system and the ability to work with as wide a variety of sites as the customer wants. But company officials make a distinction between a stance of openness and neutrality. In the process, Cardinal is trying to make the argument that rather than being disintermediated by the new B2B players, distribution-based models may ultimately prove the most robust and sustainable because of distributors' history of supply chain management.

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

IV001401

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel